If confirmed, the IGF1-19/-19 genotype may help identify a subgroup of patients for whom early breast cancer screening is warranted as well as a subgroup of patients for whom the onset of regular screening can safely be postponed. This evidence concerns the gene IGF1 and breast cancer.